

## **Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent Focal Segmental Glomerulosclerosis**

Janina Müller-Deile<sup>1\*</sup>, George Sarau<sup>2,3,4</sup>, Ahmed M Kotb<sup>1,5</sup>, Christian Jaremenko<sup>4,6</sup>, Ulrike E. Rolle-Kampczyk<sup>7</sup>, Christoph Daniel<sup>8</sup>, Stefan Kalkhof<sup>9,10</sup>, Silke Christiansen<sup>2,3,4</sup>  
and Mario Schiffer<sup>1</sup>

<sup>1</sup>Department of Nephrology and Hypertension, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, Erlangen, Germany

<sup>2</sup>Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Dresden, Germany

<sup>3</sup>Max Planck Institute for the Science of Light, Erlangen, Germany

<sup>4</sup>Institute for Nanotechnology and Correlative Microscopy eV INAM, Forchheim, Germany

<sup>5</sup>Department of Anatomy and Histology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

<sup>6</sup>Institute of Optics, Information and Photonics, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, Erlangen, Germany

<sup>7</sup>Protein biomarker unit, Department of Therapy validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany

<sup>8</sup>Department of Nephropathology, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, Erlangen, Germany

<sup>9</sup>Institute for Bioanalysis, University of Applied Sciences Coburg, Coburg, Germany

<sup>10</sup>Department of Molecular Systems Biology, Helmholtz-Centre for Environmental Research - UFZ, Leipzig, Germany

### **Supplementary material**

#### **Supplementary table 1**

Raman shift and Raman intensity of Raman measurement of <50 kDa serum fractions of a control person, FSGS patient at the time of disease recurrence and FSGS patient at the time of remission.

#### **Supplementary table 2**

Raman shift and Raman intensity of Raman measurement of podocytes treated with CTRL serum and FSGS serum.

#### **Supplementary table 3**

Raman shift and Raman intensity of Raman measurement of 0 biopsy and FSGS recurrence biopsy.

#### **Supplementary table 4**

Log2 (FSGS patient / stable transplanted control) values of metabolites measured by mass spectrometry before 1. CytoSorb, after 1. CytoSorb, mean of before 1. CytoSorb and after 1. CytoSorb (mean at recurrence), before CytoSorb at remission, after CytoSorb at remission and mean of before CytoSorb at remission, and after CytoSorb at remission (mean at remission). Difference in between Log2 (FSGS mean at remission / stable transplanted control) versus Log2 (FSGS mean at recurrence / stable transplanted control) is given together with p-value (paired, 2-sided).